Josiane Otto
About
Josiane Otto is a scholar working on Pulmonary and Respiratory Medicine, Oncology and Cancer Research.
According to data from OpenAlex, Josiane Otto has authored 59 papers receiving a total of 1.6k indexed citations (citations by other indexed papers that have themselves been cited), including 43 papers in Pulmonary and Respiratory Medicine, 37 papers in Oncology and 9 papers in Cancer Research. Recurrent topics in Josiane Otto's work include Lung Cancer Treatments and Mutations (34 papers), Lung Cancer Diagnosis and Treatment (18 papers) and Cancer Immunotherapy and Biomarkers (15 papers). Josiane Otto is often cited by papers focused on Lung Cancer Treatments and Mutations (34 papers), Lung Cancer Diagnosis and Treatment (18 papers) and Cancer Immunotherapy and Biomarkers (15 papers). Josiane Otto collaborates with scholars based in France, United States and Monaco. Josiane Otto's co-authors include M. Poudenx, Jérôme Mouroux, Nicolas Vénissac, Marius Ilié, Paul Hofman, Charles‐Hugo Marquette, Véronique Hofman, Élodie Long-Mira, L. Bouhlel and Salomé Lalvée and has published in prestigious journals such as Journal of Clinical Oncology, Blood and Cancer.
In The Last Decade
Josiane Otto
56 papers receiving 1.6k citations
Hit Papers
Peers — A (Enhanced Table)
Peers by citation overlap · career bar shows stage (early→late) cites · hero ref
| Name | h | Career | Trend | Papers | Cites | |||||
|---|---|---|---|---|---|---|---|---|---|---|
| Josiane Otto France | 20 | 1.1k | 906 | 259 | 228 | 204 | 59 | 1.6k | ||
| Jessica Menis Italy | 21 | 1.2k 1.1× | 1.1k 1.2× | 363 1.4× | 381 1.7× | 185 0.9× | 76 | 1.9k | ||
| M. Poudenx France | 16 | 1.3k 1.2× | 1.1k 1.2× | 408 1.6× | 225 1.0× | 174 0.9× | 41 | 1.7k | ||
| Yuka Fujita Japan | 21 | 1.2k 1.1× | 1.2k 1.4× | 280 1.1× | 321 1.4× | 126 0.6× | 77 | 1.8k | ||
| Miso Kim South Korea | 25 | 1.2k 1.1× | 710 0.8× | 208 0.8× | 292 1.3× | 95 0.5× | 87 | 1.7k | ||
| Sung‐Ja Ahn South Korea | 21 | 512 0.5× | 619 0.7× | 311 1.2× | 175 0.8× | 308 1.5× | 113 | 1.5k | ||
| Alice Chen United States | 7 | 1.3k 1.2× | 624 0.7× | 221 0.9× | 156 0.7× | 332 1.6× | 14 | 1.8k | ||
| Myung‐Ju Ahn South Korea | 20 | 792 0.7× | 990 1.1× | 139 0.5× | 250 1.1× | 159 0.8× | 75 | 1.5k | ||
| R. Rosell Spain | 17 | 1.2k 1.1× | 1.7k 1.9× | 250 1.0× | 399 1.8× | 216 1.1× | 113 | 2.2k | ||
| Édith Borcoman France | 17 | 948 0.9× | 419 0.5× | 170 0.7× | 239 1.0× | 152 0.7× | 50 | 1.3k | ||
| Ke‐Neng Chen China | 21 | 882 0.8× | 1.0k 1.2× | 334 1.3× | 272 1.2× | 155 0.8× | 77 | 1.7k |
Countries citing papers authored by Josiane Otto
Since
Specialization
Citations
This map shows the geographic impact of Josiane Otto's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Josiane Otto with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Josiane Otto more than expected).
Fields of papers citing papers by Josiane Otto
Since
Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences
This network shows the impact of papers produced by Josiane Otto. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Josiane Otto. The network helps show where Josiane Otto may publish in the future.
Co-authorship network of co-authors of Josiane Otto
This figure shows the co-authorship network connecting the top 25 collaborators of Josiane Otto. A scholar is included among the top collaborators of Josiane Otto based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Josiane Otto. Josiane Otto is excluded from the visualization to improve readability, since they are connected to all nodes in the network.
All Works
1.
Chardin, David, et al.. (2024). Total metabolic tumor volume on 18F-FDG PET/CT is a game-changer for patients with metastatic lung cancer treated with immunotherapy. Journal for ImmunoTherapy of Cancer. 12(4). e007628–e007628.
2.
Benzaquen, Jonathan, Pierre‐Yves Bondiau, Josiane Otto, et al.. (2023). Comparison of outcome after stereotactic ablative radiotherapy of patients with metachronous lung versus primary lung cancer. Radiation Oncology. 18(1). 97–97.
3.
Ilié, Marius, Jonathan Benzaquen, Simon Heeke, et al.. (2022). Deep Learning Facilitates Distinguishing Histologic Subtypes of Pulmonary Neuroendocrine Tumors on Digital Whole-Slide Images. Cancers. 14(7). 1740–1740.
4.
Girard, Nicolas, Julien Mazières, Josiane Otto, et al.. (2021). LBA41 Nivolumab (nivo) ± ipilimumab (ipi) in pre-treated patients with advanced, refractory pulmonary or gastroenteropancreatic poorly differentiated neuroendocrine tumors (NECs) (GCO-001 NIPINEC). Annals of Oncology. 32. S1318–S1318.
5.
Nadal, Ernest, Simon Heeke, Jonathan Benzaquen, et al.. (2020). Two Patients With Advanced-Stage Lung Adenocarcinoma With Radiologic Complete Response to Nivolumab Treatment Harboring an STK11/LKB1 Mutation. JCO Precision Oncology. 4(4). 1239–1245.
6.
Girard, Nicolas, M. Duruisseaux, Virginie Avrillon, et al.. (2020). 1349P Lorlatinib for advanced ROS1+ non-small cell lung cancer (NSCLC): Efficacy and safety data from IFCT-1803 LORLATU expanded access program (EAP) cohort. Annals of Oncology. 31. S865–S865.
7.
Baldacci, Simon, Benjamin Besse, Virginie Avrillon, et al.. (2020). 1303P Lorlatinib for advanced ALK+ non-small cell lung cancer (NSCLC): Efficacy and safety data from IFCT-1803 LORLATU expanded access program (EAP) cohort. Annals of Oncology. 31. S843–S843.
8.
Bouhlel, L., J. Doyen, Emmanuel Chamorey, et al.. (2020). Occurrence and number of immune-related adverse events are independently associated with survival in advanced non-small-cell lung cancer treated by nivolumab. Bulletin du Cancer. 107(9). 946–958.
9.
Gal, Jocelyn, Nathalie Ebran, Josiane Otto, et al.. (2019). Germinal Immunogenetics predict treatment outcome for PD-1/PD-L1 checkpoint inhibitors. Investigational New Drugs. 38(1). 160–171.
10.
Humbert, Olivier, Renaud Schiappa, M. Poudenx, et al.. (2019). 18FDG PET/CT in the early assessment of non-small cell lung cancer response to immunotherapy: frequency and clinical significance of atypical evolutive patterns. European Journal of Nuclear Medicine and Molecular Imaging. 47(5). 1158–1167.
11.
Bondiau, Pierre‐Yves, M. Poudenx, Charlotte Cohen, et al.. (2019). Long term efficacy and toxicity after stereotactic ablative reirradiation in locally relapsed stage III non-small cell lung cancer. BMC Cancer. 19(1). 305–305.
12.
Quoix, Élisabeth, Clarisse Audigier-Valette, A. Lavolé, et al.. (2018). Maintenance chemotherapy versus follow-up after carboplatin and weekly paclitaxel doublet chemotherapy in elderly patients with advanced non-small cell lung cancer (NSCLC): IFCT-1201 MODEL randomised phase III trial. Annals of Oncology. 29. viii744–viii745.
13.
Moro‐Sibilot, Denis, Nathalie Cozic, M. Pérol, et al.. (2018). OA12.03 Activity of Crizotinib in MET or ROS1 Positive (+) NSCLC: Results of the AcSé Trial.. Journal of Thoracic Oncology. 13(10). S348–S348.
14.
Ilié, Marius, Élodie Long-Mira, Coraline Bence, et al.. (2015). Comparative study of the PD-L1 status between surgically resected specimens and matched biopsies of NSCLC patients reveal major discordances: a potential issue for anti-PD-L1 therapeutic strategies. Annals of Oncology. 27(1). 147–153.
15.
Poudenx, M., Pierre‐Yves Bondiau, Emmanuel Chamorey, et al.. (2012). Cisplatin-Docetaxel Induction plus Concurrent 3-D Conformal Radiotherapy and Weekly Chemotherapy for Locally Advanced Non-Small Cell Lung Cancer Patients: A Phase II Trial. Oncology. 83(6). 321–328.
16.
Castelli, J., Juliette Thariat, Karen Bénézery, et al.. (2008). Analyse de la toxicité précoce des traitements par Cyberknife® des cancers pulmonaires et résultats préliminaires. Cancer/Radiothérapie. 12(8). 793–799.
17.
Leo, Francesco, Nicolas Vénissac, M. Poudenx, Josiane Otto, & Jérôme Mouroux. (2007). Multidisciplinary Management of Lung Cancer: How to Test Its Efficacy?. Journal of Thoracic Oncology. 2(1). 69–72.
18.
Guardiola, Emmanuel, X. Pivot, O. Dassonville, et al.. (2004). Is routine triple endoscopy for head and neck carcinoma patients necessary in light of a negative chest computed tomography scan?. Cancer. 101(9). 2028–2033.
19.
Chatelut, Étienne, Xavier Pivot, Josiane Otto, et al.. (2000). A limited sampling strategy for determining carboplatin AUC and monitoring drug dosage. European Journal of Cancer. 36(2). 264–269.
20.
Schneider, M., M C Etienne, G. Milano, et al.. (1995). Phase II trial of cisplatin, fluorouracil, and pure folinic acid for locally advanced head and neck cancer: a pharmacokinetic and clinical survey.. Journal of Clinical Oncology. 13(7). 1656–1662.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.
Explore authors with similar magnitude of impact
Breakdown of academic impact, for papers by Jessica Menis Breakdown of academic impact, for papers by M. Poudenx Breakdown of academic impact, for papers by Yuka Fujita Breakdown of academic impact, for papers by Miso Kim Breakdown of academic impact, for papers by Sung‐Ja Ahn Breakdown of academic impact, for papers by Alice Chen Breakdown of academic impact, for papers by Myung‐Ju Ahn Breakdown of academic impact, for papers by R. Rosell Breakdown of academic impact, for papers by Édith Borcoman Breakdown of academic impact, for papers by Ke‐Neng Chen